Accueil   Diary - News   All news Adocia strengthens its BioChaperone Combo patent porfolio

Adocia strengthens its BioChaperone Combo patent porfolio

Adocia (Euronext Paris: FR0011184241 – ADOC) announced that the two major patent families covering BioChaperone Combo were granted in two of the main potential markets for this product. BioChaperone Combo is a unique combination, enabled by proprietary BioChaperone technology, of the basal insulin glargine and the prandial insulin lispro. BioChaperone Combo has been successfully tested in 3 different clinical studies in subjects with type 1 and type 2 diabetes and is one of Adocia’s lead clinical development programs.

 

Read the press release